SANOFI-AVENTIS (EPA:SAN) Press Release: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)
Directive transparence : information réglementée
31/08/2022 20:30
01/06/2023 07:30
01/06/2023 07:30
21/05/2023 20:17
21/05/2023 20:17
17/05/2023 22:01
17/05/2023 22:01
12/05/2023 10:50
04/05/2023 08:00
04/05/2023 08:00
27/04/2023 14:40